• Publications
  • Influence
Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.
There is currently widespread interest in the IGFs (IGF-I and IGF-II) and their roles in the regulation of growth and differentiation of an ever increasing number of tissues are being reported. ThisExpand
  • 1,807
  • 48
Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.
No agreement exists concerning the necessity for extracting serum somatomedin (Sm) before radioreceptor assay (RRA) and RIA. We have developed a simplified system of Sm extraction which has permittedExpand
  • 773
  • 18
Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia.
We describe a case of recurrent hypoglycemia apparently caused by secretion of insulin-like growth factor II (IGF-II) by a leiomyosarcoma. A 67-year-old woman presented with recurrent severeExpand
  • 313
  • 10
A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro.
  • 1,031
  • 8
Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors.
In some subjects with hypoglycemia associated with tumors of mesenchymal origin, high insulin-like growth factor-II (IGF-II) levels have been described in serum and in the tumors. Tumor IGF-II ofExpand
  • 101
  • 7
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and appears to arise from developing striated muscle-forming cells. Since insulin-like growth factor II (IGF-II) is involved inExpand
  • 249
  • 6
  • PDF
Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.
The insulin-like growth factor II (IGF-II) gene is overexpressed in many mesenchymal tumors and can lead to non-islet-cell tumor hypoglycemia (NICTH). ProIGF-II consists of the 67 aa of IGF-II with aExpand
  • 87
  • 6
Somatomedin: Proposed Designation for Sulphation Factor
THE action of growth hormone (GH) on skeletal tissue was proposed to be mediated through a secondary substance, described by the operational term “sulphation factor”1. The observations underlyingExpand
  • 815
  • 5
Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia.
The human glucocorticoid receptor (GR) is expressed as two alternatively spliced isoforms, GRalpha and GRbeta. Whereas GRalpha is a hormone-activated transcription factor, GRbeta does not bindExpand
  • 119
  • 4